A phase I/II, dual-center, open-label trial of the safety and efficacy of Tarceva (erlotinib hydrochloride) plus sirolimus in patients with recurrent malignant glioma not on P450-inducing anti-epileptics

Trial Profile

A phase I/II, dual-center, open-label trial of the safety and efficacy of Tarceva (erlotinib hydrochloride) plus sirolimus in patients with recurrent malignant glioma not on P450-inducing anti-epileptics

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Erlotinib (Primary) ; Sirolimus (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Feb 2016 Study phase changed from phase I/II to phase I, as phase II of the study was not conducted, as reported by ClinicalTrials.gov.
    • 27 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top